ZA987726B - 2-aminopyridines containing fused ring substituents. - Google Patents

2-aminopyridines containing fused ring substituents.

Info

Publication number
ZA987726B
ZA987726B ZA9807726A ZA987726A ZA987726B ZA 987726 B ZA987726 B ZA 987726B ZA 9807726 A ZA9807726 A ZA 9807726A ZA 987726 A ZA987726 A ZA 987726A ZA 987726 B ZA987726 B ZA 987726B
Authority
ZA
South Africa
Prior art keywords
fused ring
ring substituents
containing fused
aminopyridines containing
aminopyridines
Prior art date
Application number
ZA9807726A
Other languages
English (en)
Inventor
Iii John Adams Lowe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA987726B publication Critical patent/ZA987726B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9807726A 1997-08-27 1998-08-26 2-aminopyridines containing fused ring substituents. ZA987726B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5709497P 1997-08-27 1997-08-27

Publications (1)

Publication Number Publication Date
ZA987726B true ZA987726B (en) 2000-02-28

Family

ID=22008463

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9807726A ZA987726B (en) 1997-08-27 1998-08-26 2-aminopyridines containing fused ring substituents.

Country Status (40)

Country Link
EP (1) EP1007520B1 (da)
JP (1) JP3411271B2 (da)
KR (1) KR100367277B1 (da)
CN (1) CN1268133A (da)
AP (1) AP1213A (da)
AR (1) AR014110A1 (da)
AT (1) ATE248161T1 (da)
AU (1) AU8458898A (da)
BG (1) BG104138A (da)
BR (1) BR9811555A (da)
CA (1) CA2296313C (da)
CO (1) CO4970728A1 (da)
DE (1) DE69817584T2 (da)
DK (1) DK1007520T3 (da)
DZ (1) DZ2594A1 (da)
EA (1) EA003839B1 (da)
ES (1) ES2203976T3 (da)
GT (1) GT199800128A (da)
HN (1) HN1998000118A (da)
HR (1) HRP980470A2 (da)
HU (1) HUP0003700A3 (da)
ID (1) ID24087A (da)
IL (1) IL133958A0 (da)
IS (1) IS5344A (da)
MA (1) MA26537A1 (da)
NO (1) NO20000958L (da)
NZ (1) NZ502281A (da)
OA (1) OA11288A (da)
PA (1) PA8456901A1 (da)
PE (1) PE106599A1 (da)
PL (1) PL338987A1 (da)
PT (1) PT1007520E (da)
SK (1) SK1402000A3 (da)
TN (1) TNSN98154A1 (da)
TR (1) TR200000535T2 (da)
UA (1) UA55461C2 (da)
UY (1) UY25158A1 (da)
WO (1) WO1999010339A1 (da)
YU (1) YU10900A (da)
ZA (1) ZA987726B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
SK15072000A3 (sk) 1998-04-10 2001-08-06 Japan Tobacco Inc. Amidové zlúčeniny
CN1303379A (zh) * 1998-06-03 2001-07-11 辉瑞产品公司 作为氧化氮合酶抑制剂的含稠环取代基的2－氨基吡啶
HUP0103113A3 (en) * 1998-08-11 2002-02-28 Pfizer Prod Inc New pharmaceutical compositions uses for nos inhibitors
CA2364719C (en) 1999-02-25 2006-07-04 Pfizer Products Inc. 2-aminopyridines containing fused ring substituents
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004149D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
AU2001283393B2 (en) * 2000-08-16 2005-09-22 Pharmacia & Upjohn Company Compounds for the treatment of addictive disorders
RU2278859C2 (ru) 2001-05-15 2006-06-27 Ф.Хоффманн-Ля Рош Аг Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета
SE0102640D0 (sv) 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10159922A1 (de) * 2001-12-06 2003-06-26 Gruenenthal Gmbh Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate
PL374818A1 (en) 2002-07-03 2005-10-31 F.Hoffmann-La Roche Ag Oxazole derivatives and their use as insulin sensitizers
MXPA05001702A (es) * 2002-08-14 2005-04-19 Neurosearch As Derivados de quinuclidina novedosos y su uso.
ATE483699T1 (de) 2002-08-30 2010-10-15 Hoffmann La Roche Neue 2-arylthiazolverbindungen als ppar-alpha und gamma agonisten
WO2004024726A1 (en) 2002-09-12 2004-03-25 F. Hoffmann-La Roche Ag N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
US20040092741A1 (en) * 2002-11-08 2004-05-13 Pfizer Inc Substituted pyridines via boronic acid coupling
DE60323130D1 (de) 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
US7160876B2 (en) * 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2006065233A1 (en) * 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7655657B2 (en) 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20080194547A1 (en) * 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
WO2009029617A1 (en) * 2007-08-27 2009-03-05 Kalypsys, Inc. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
TW200924772A (en) * 2007-08-27 2009-06-16 Kalypsys Inc Heterobicyclic-substituted quinolones useful as nitric oxide synthase inhibitors
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
DE102008054141A1 (de) 2008-10-31 2010-05-06 Merck Patent Gmbh Neue Materialien für organische Elektrolumineszenzvorrichtungen
DE102009033371A1 (de) 2009-07-16 2011-05-12 Merck Patent Gmbh Materialien für elektronische Vorrichtungen
WO2014138460A1 (en) 2013-03-07 2014-09-12 Northwestern University 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors
CN104725249B (zh) * 2013-12-20 2019-02-12 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
WO2016073623A2 (en) 2014-11-04 2016-05-12 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
US10759791B2 (en) 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
CN106478376A (zh) * 2016-10-08 2017-03-08 贵州大学 一种4‑氟萘‑1‑醇的制备工艺
ES3050624T3 (en) * 2018-12-17 2025-12-22 Godavari Biorefineries Ltd Compounds for the inhibition of unregulated cell growth
US12213973B2 (en) 2021-10-18 2025-02-04 Northwestern University Bacterial nitric oxide synthase inhibitors
CN114560779B (zh) * 2022-01-25 2024-06-25 杭州华东医药集团浙江华义制药有限公司 一种米拉贝隆关键中间体的合成方法
CN116059206A (zh) * 2023-03-03 2023-05-05 天津医科大学总医院 2-氨基喹啉在治疗腹泻药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT400845B (de) * 1993-12-06 1996-03-25 Chem Pharm Forsch Gmbh Neue thienothiazinderivate, ein verfahren zu ihrer herstellung und ihre verwendung
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
JPH08311028A (ja) * 1995-05-17 1996-11-26 Japan Tobacco Inc ２−アミノピリジン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤
JPH09132529A (ja) * 1995-11-09 1997-05-20 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
NZ326874A (en) 1996-03-29 2000-01-28 Pfizer 6-phenylpyridyl-2-amine derivatives
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina

Also Published As

Publication number Publication date
DK1007520T3 (da) 2003-11-24
PL338987A1 (en) 2000-12-04
CA2296313C (en) 2004-11-02
PE106599A1 (es) 1999-11-02
WO1999010339A1 (en) 1999-03-04
YU10900A (sh) 2002-12-10
NO20000958L (no) 2000-04-14
DE69817584D1 (de) 2003-10-02
DE69817584T2 (de) 2004-04-01
AP9801330A0 (en) 1998-09-30
CN1268133A (zh) 2000-09-27
PT1007520E (pt) 2003-12-31
IS5344A (is) 2000-01-14
AU8458898A (en) 1999-03-16
ID24087A (id) 2000-07-06
OA11288A (en) 2003-08-22
HN1998000118A (es) 1999-02-09
BG104138A (en) 2000-11-30
EP1007520A1 (en) 2000-06-14
AP1213A (en) 2003-10-07
JP3411271B2 (ja) 2003-05-26
HRP980470A2 (en) 1999-06-30
KR20010022433A (ko) 2001-03-15
BR9811555A (pt) 2000-09-12
GT199800128A (es) 2000-02-01
MA26537A1 (fr) 2004-12-20
AR014110A1 (es) 2001-02-07
NO20000958D0 (no) 2000-02-25
UA55461C2 (uk) 2003-04-15
IL133958A0 (en) 2001-04-30
ES2203976T3 (es) 2004-04-16
KR100367277B1 (ko) 2003-01-09
TNSN98154A1 (fr) 2005-03-15
TR200000535T2 (tr) 2000-11-21
PA8456901A1 (es) 2000-05-24
NZ502281A (en) 2002-09-27
UY25158A1 (es) 2000-12-29
SK1402000A3 (en) 2000-07-11
DZ2594A1 (fr) 2003-02-22
HUP0003700A2 (hu) 2001-10-28
EP1007520B1 (en) 2003-08-27
CA2296313A1 (en) 1999-03-04
EA200000171A1 (ru) 2000-10-30
CO4970728A1 (es) 2000-11-07
JP2001514176A (ja) 2001-09-11
EA003839B1 (ru) 2003-10-30
ATE248161T1 (de) 2003-09-15
HUP0003700A3 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
HUP0003700A3 (en) 2-aminopyridines containing fused ring substituents as nos inhibitors
ZA9811911B (en) Aryl fused azapolycyclic compounds.
CY2464B1 (en) Toothbrush.
ZA979593B (en) Naphthyridine derivatives.
ZA982853B (en) Nicotinamide derivatives.
ZA981870B (en) Toothbrush.
GB2324840B (en) Sealing ring
AU5648899A (en) Fused ring compound
GB0022723D0 (en) Retaining ring
GB2321285B (en) Coaxial sealing ring
ZA9810271B (en) Fused pyrazine compounds
GB9806332D0 (en) Synchronizer ring
IL144308A0 (en) 2-aminopyridines containing fused ring substituents
GB9812207D0 (en) Ring binder
ZA979617B (en) Novel heterocyclic compounds.
ZA993699B (en) 2-aminopyridines containing fused ring substituents.
ZA982436B (en) Thiazolimine derivatives.
HU9802275D0 (en) Sealing ring
GB9921429D0 (en) Ring oscillator
GB9716101D0 (en) Fused heterocyclic compounds
SI1007520T1 (en) 2-aminopyridines containing fused ring substituents as nos inhibitors
ZA981307B (en) 4-aminoethoxyindazole derivatives.
AU2002300085A1 (en) 2-aminopyridines Containing Fused Ring Substituents as NOS Inhibitors
GB9723206D0 (en) New cytotoxic pyridoacridine alkaloids
GB9821941D0 (en) Ring binder